Clinical trial
Second-Line Treatment Choice for Epilepsy
NCT00208520 · Dutch Epilepsy Clinics Foundation, Other · Unknown status
Key facts
| NCT number | NCT00208520 |
|---|---|
| Title | Second-Line Treatment Choice for Epilepsy |
| Official title | Second-Line Treatment Choice for Epilepsy |
| Lead sponsor | Dutch Epilepsy Clinics Foundation, Other |
| Status | Unknown status |
| Study type | Interventional |
| Conditions | Adults With Tonic Clonic Seizures and/or Partial Seizures |
| Intervention type | Drug |
| Interventions | Carbamazepine, Lamotrigine, Levetiracetam |
| Enrollment | 60 |
| Start date | Jul 1, 2003 |
| Completion | Jun 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | Sep 12, 2006 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: